Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors

Cancer Research

Volumn 56, Issue 21, 1996, Pages 4917-4921

  Von Brevern, Marie Charlotte ^a   Hollstein, Monica C ^a   Cawley, Helen M ^b   De Benedetti, Virna M G ^b,f   Bennett, William P ^b   Liang, Linda ^b,g   He, An Guang ^c   Zhu, Simin M ^d   Tursz, Thomas ^e   Janin, Nicolas ^e   Trivers, Glenwood E ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

^c CHINA MEDICAL UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY   (China)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; PROTEIN P53;

ANTIBODY RESPONSE; ARTICLE; CANCER PATIENT; ENZYME IMMUNOASSAY; ESOPHAGUS CANCER; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; ESOPHAGEAL NEOPLASMS; FEMALE; GENES, P53; HUMANS; MALE; MIDDLE AGED; MUTATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 10344262596     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Crawford, L V., Pim, D. C, and Bulbrook, R. D Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int. J. Cancer, 30: 403-408, 1982.
2. Labreque, S, Naor, N., Thomson, D., and Matlashewski, G Analysis of the anti-p53 antibody response in cancer patients. Cancer Res., 53: 3468-3471, 1993
3. Rainov, N, G, Dobberstein, K-U., Fittkau, M., Bahn, H., Holzhausen, H-J., Gantchev, L, and Burkert, W Absence of p53 autoantibodies in sera from glioma patients. Clin. Cancer Res., 1 775-781, 1995.
4. Angelopoulou, K., Diamandis, E. P, Sutherland, D. J. A., Kellen, J A., and Bunting, P. S Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int. J. Cancer, 58: 480-487, 1994.
5. Vojtesek, B., Kovarik, J U., Dolezalova, H, Nenutil, R., Havlis, P., Brentani, R R., and Lane, D. Absence of p53 autoantibodies in a significant proportion of breast cancer patients. Br. J. Cancer, 71 1253-1256, 1995.
6. Lubin, R, Schlichtholz, B., Bengoufa, D., Zalcman, G., Tredaniel, J., Hirsch, A., Caron-de Formentel, C., Preudhomme, C, Fenaux, P., Fournier, G., Mangon, P, Laurent-Puig, P., Pelletier, G, Schlumberger, M., Desgrandchamps, F., Le Duc, A., Peyrat, J. P., Janin, N, Bressac, B, and Soussi, T. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface Cancer Res., 53: 5872-5876, 1993
7. Winter, S. F., Minna, J. D, Johnson, B. E., Takahashi, T, Gazdar, A F., and Carbone, D P. Development of antibodies against p53 in lung cancer patients appears to be dependent upon the type of p53 mutation Cancer Res., 53: 4168-4174, 1992.
8. Harris, C C., and Hollstein, M. Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med., 329: 1318-1327, 1993.
9. Sidransky, D., and Hollstein, M. Clinical implications of the p53 gene. Annu. Rev Med., 47: 285-301, 1996.
10. Wild, C. P., Ridanpaä, M., Anttila, S., Lubin, R., Soussi, T., Husgafvel-Pursiainen, K, and Vainio, H p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue. Int. J. Cancer (Pred. Oncol.), 64: 176-181, 1995.
11. Davidoff, A. M, Iglehart, J. D, and Marks, J. R. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad. Sci. USA, 89: 3439-3442, 1992
12. Preudhomme, C., Lubin, R., Lepelley, P., Vanrumbeke, M, and Fenaux, P. Detection of serum anti-p53 antibodies and their correlation with p53 mutations in myelodysplastic syndromes and acute myeloid leukemia Leukemia (Baltimore), 8 1589-1591, 1994
13. Guinee, D. G., Jr., Trivis, W. D, Trivers, G. E, De Benedetti, V M. G., Cawley, H, Welsh, J., Bennett, W., Jett, J., Colgy, T V., and Tazelaar, S. L. Gender comparisons in human lung cancer analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression Carcinogenesis (Lond), 16 993-1002, 1995.
14. Greenblatt, M. S, Bennett, W P., Hollstein, M., and Harris, C C Mutations in the p53 tumor suppressor gene, clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.
15. Hollstein, M., Sidransky, D., Vogelstein, B, and Harris, C. C. p53 mutations in human cancers Science (Washington DC), 253: 49-53, 1991
16. Audrezet, M. P., Robaszkiewicz, M., Mercier, B., Nousbaum, J. B., Bail, J. P., Hardy, E, Volant, A, Lozac'h, P, Charles, J. F, Gouerou, H., and Ferec, C. TP53 gene mutation profile in esophageal squamous cell carcinomas. Cancer Res., 53: 5745-5749, 1993.
17. Huang, Y., Meltzer, S. J, Yin, J., Tong, Y., Chang, E. H., Srivastava, S., McDaniel, T., Boynton, R. F., and Zou, Z-Q. Altered messenger RNA and unique mutational profiles of p53 and Rb in human esophageal carcinomas. Cancer Res., 53: 1889-1894, 1993
18. Liang, Y. Y., Esteve, A., Martel-Planche, G., Takahashi, S., Lu, S-H, Montesano, R., and Hollstein, M p53 mutations in esophageal tumors from high-incidence areas of China. Int. J Cancer, 61: 611-614, 1995.
19. Bennett, W., Hollstein, M., Metcalf, R. A, Welsh, J., He, A., Si-min, Z., Kusters, L, Resau, J H, Thrump, B. J, Lane, D. P., and Harris, C. C p53 mutations and protein accumulation during multistage human esophageal carcinoma. Cancer Res., 53: 6092-6097, 1992.
20. Gao, H., Wang, L. D., Zhou, Q., Hong, J. Y., Huang, T. Y., and Yang, C. S. p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China. Cancer Res., 54: 4342-4346, 1994.
21. Trivers, G. E., Cawley, H L, DeBenedetti, V M. G, Hollstein, M, Marion, M. J., Bennett, W. P., Hoover, M. L., Prives, C., Tamburro, C., and Harris, C. C. Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. J Natl. Cancer Inst., 87: 1400-1407, 1995
22. Lubin, R. Zalcman, G., Bouchet, L., Tredaniel, J., Legros, Y., Cazals, D., Hirsch, A., and Soussi, T. Serum p53 antibodies as early markers of lung cancer. Nat. Med., 1: 701-702, 1995.
23. Munoz, N., and Castellsague, X. Epidemiology of oesophageal cancer Eur J. Gastroenterol. Hepatol., 6: 649-655, 1994.
24. Parkin, D. M, Pisani, P., and Ferlay, I. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J. Cancer, 54: 594-606, 1993.
25. Berrino, F., Sant, M., Verdecchia, A., Capocaccia, R., Hakulinen, T. and Esteve, J. Survival of cancer patients in Europe: the Eurocare study, Vol. 132. Lyon, France: IARC, 1995.
26. Bennett, W. P., Hollstein, M. C., He, A, Zhu, S. M., Resau, J. H, Trump, B. F., Metcalf, R. A, Welsh, J. A., Midgley, D. P., and Harris, C. C. Archival analysis of p53 genetic alterations in Chinese esophageal cancer. Oncogene, 6: 1779-1784, 1991
27. Hamelin, R., Jego, N., Laurent-Puig, P, Vidaud, M, and Thomas, G. Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors. Oncogene, 8 2213-2220, 1993.
28. Renault, B., van den Broek, M., Fodde, R, Wijnen, J., Pellegata, N S, Amadori, D., Khan, P. M., and Ranzani, G. N. Base transitions are the most frequent genetic changes at p53 in gastric cancer Cancer Res, 53: 2614-2617, 1993.
29. Cho, Y, Gorina, S., Jeffrey, P. D., and Pavletich, N. P. Crystal structure of p53 tumor suppressor-DNA complex: understanding tumorigenic mutations Science (Washington DC), 265: 346-355, 1994.
30. Prives, C. How loops, β sheets, and α helices help us to understand p53 Cell, 78: 543-548, 1994
31. Rolley, N., Butcher, S., and Milner, J. Specific DNA binding by different classes of human p53 mutants. Oncogene, 11: 763-770, 1995.
32. Momand, J, Zambetti, G. P, Olson, D. C., George, D., and Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation Cell, 69: 1237-1245, 1992.
33. Vogelstein, B., and Kinzler, K. W p53 function and dysfunction. Cell, 70: 523-526, 1992
34. Winter, S. F., Sekido, Y, Minna, J. D., McIntire, D., Johnson, B E, Gazdar, A. F., and Carbone, D. P Antibodies against autologous tumor cell proteins in patients with small cell lung cancer: association with improved survival. J Natl Cancer Inst., 85: 2012-2018, 1993.
35. Nanda, N. K, and Sercarz, E E. Induction of anti-self-immunity to cure cancer. Cell, 82: 13-17, 1995.
36. Schlichtholz, B, Legros, Y., Gillet, D., Gaillard, C., Marty, M., Lane, D, Calvo, F, and Soussi, T The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res., 52: 6380-6384, 1992.
37. Milner, J DNA damage, p53 and anticancer therapies. Nat. Med., 1: 879-880, 1995
38. Dong, X., Hamilton, K. J, Satoh, M., Wang, J, and Reeves, W H Initiation of autoimmunity to the p53 tumor suppressor protein by complexes of p53 and SV40 large T antigen. J. Exp. Med, 179: 1243-1252, 1994.
39. Wiedenfeld, E. A, Fernandez-Vina, M., Berzofsky, J A., and Carbone, D. P. Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A*0201 peptide consensus motif Cancer Res., 54: 1175-1177, 1994.